Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISILI: Intratumoral Ipilimumab and GLA-SE with Systemic Nivolumab and FOLFOX in Colorectal Liver Metastases
NCT03982121Phase 1Withdrawn
- Sponsor
- Gustave Roussy
- Start
- Jun 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules, Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of ipilimumab and GLA-SE adjuvant in colorectal cancer (CRC) (6 arms), sponsored by Gustave Roussy. Primary endpoints: Maximum Tolerated Dose at 28 days and Recommended Phase 2 Dose at 8 weeks. Planned start Jun 2019; status: withdrawn.
02
Drugs
ipilimumabGLA-SE adjuvant
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03982121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03982121.